Cargando…

The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials

Facial seborrheic dermatitis (SD) is a chronic inflammatory skin condition that can affect the quality of life with frequent recurrences. There is no medication as yet to cure this disease completely. There are four general categories of agents that are used to treat SD: antifungal agents, keratolyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsmeirat, Odeh, Lakhani, Som, Egaimi, Musab, Idris, Osama, Elkhalifa, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436712/
https://www.ncbi.nlm.nih.gov/pubmed/36072203
http://dx.doi.org/10.7759/cureus.27622
_version_ 1784781431879237632
author Alsmeirat, Odeh
Lakhani, Som
Egaimi, Musab
Idris, Osama
Elkhalifa, Mohamed
author_facet Alsmeirat, Odeh
Lakhani, Som
Egaimi, Musab
Idris, Osama
Elkhalifa, Mohamed
author_sort Alsmeirat, Odeh
collection PubMed
description Facial seborrheic dermatitis (SD) is a chronic inflammatory skin condition that can affect the quality of life with frequent recurrences. There is no medication as yet to cure this disease completely. There are four general categories of agents that are used to treat SD: antifungal agents, keratolytics, corticosteroids, and lastly calcineurin inhibitors. Topical therapies are the mainstream line of treatment to be used for this skin condition. The objective of this article is to critically review the published data in the literature on the use of topical pimecrolimus 1% topical cream as an option for treating facial SD. The final purpose of this review is to answer two questions: whether pimecrolimus topical cream is effective for the treatment of SD compared to the conventional current treatments and how safe is this treatment.  The PubMed, Clinicaltrials.gov, MEDLINE + Embase, and Cochrane library databases were searched for original randomized clinical trials (RCTs) evaluating pimecrolimus 1% topical cream and comparing it with other topical treatments for SD. A systematic review and meta-analysis were then conducted on the selected studies by grading the evidence and qualitative comparison of results among and within studies. A total of five studies were included in the review; however, only four were eligible for inclusion in the meta-analysis, in which pimecrolimus was compared with other treatments for the management of facial SD. Pimecrolimus was found to be an effective topical treatment for facial SD, as it showed considerable desirable control of the symptoms in patients with facial SD clinically, in addition to a lower recurrence or relapsing rates; however, it had more side effects compared to other topical treatments, but the side effects were mild and tolerable.
format Online
Article
Text
id pubmed-9436712
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-94367122022-09-06 The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials Alsmeirat, Odeh Lakhani, Som Egaimi, Musab Idris, Osama Elkhalifa, Mohamed Cureus Dermatology Facial seborrheic dermatitis (SD) is a chronic inflammatory skin condition that can affect the quality of life with frequent recurrences. There is no medication as yet to cure this disease completely. There are four general categories of agents that are used to treat SD: antifungal agents, keratolytics, corticosteroids, and lastly calcineurin inhibitors. Topical therapies are the mainstream line of treatment to be used for this skin condition. The objective of this article is to critically review the published data in the literature on the use of topical pimecrolimus 1% topical cream as an option for treating facial SD. The final purpose of this review is to answer two questions: whether pimecrolimus topical cream is effective for the treatment of SD compared to the conventional current treatments and how safe is this treatment.  The PubMed, Clinicaltrials.gov, MEDLINE + Embase, and Cochrane library databases were searched for original randomized clinical trials (RCTs) evaluating pimecrolimus 1% topical cream and comparing it with other topical treatments for SD. A systematic review and meta-analysis were then conducted on the selected studies by grading the evidence and qualitative comparison of results among and within studies. A total of five studies were included in the review; however, only four were eligible for inclusion in the meta-analysis, in which pimecrolimus was compared with other treatments for the management of facial SD. Pimecrolimus was found to be an effective topical treatment for facial SD, as it showed considerable desirable control of the symptoms in patients with facial SD clinically, in addition to a lower recurrence or relapsing rates; however, it had more side effects compared to other topical treatments, but the side effects were mild and tolerable. Cureus 2022-08-02 /pmc/articles/PMC9436712/ /pubmed/36072203 http://dx.doi.org/10.7759/cureus.27622 Text en Copyright © 2022, Alsmeirat et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Alsmeirat, Odeh
Lakhani, Som
Egaimi, Musab
Idris, Osama
Elkhalifa, Mohamed
The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials
title The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials
title_full The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials
title_fullStr The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials
title_full_unstemmed The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials
title_short The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials
title_sort efficacy and safety of pimecrolimus in patients with facial seborrheic dermatitis: a systematic review of randomized controlled trials
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436712/
https://www.ncbi.nlm.nih.gov/pubmed/36072203
http://dx.doi.org/10.7759/cureus.27622
work_keys_str_mv AT alsmeiratodeh theefficacyandsafetyofpimecrolimusinpatientswithfacialseborrheicdermatitisasystematicreviewofrandomizedcontrolledtrials
AT lakhanisom theefficacyandsafetyofpimecrolimusinpatientswithfacialseborrheicdermatitisasystematicreviewofrandomizedcontrolledtrials
AT egaimimusab theefficacyandsafetyofpimecrolimusinpatientswithfacialseborrheicdermatitisasystematicreviewofrandomizedcontrolledtrials
AT idrisosama theefficacyandsafetyofpimecrolimusinpatientswithfacialseborrheicdermatitisasystematicreviewofrandomizedcontrolledtrials
AT elkhalifamohamed theefficacyandsafetyofpimecrolimusinpatientswithfacialseborrheicdermatitisasystematicreviewofrandomizedcontrolledtrials
AT alsmeiratodeh efficacyandsafetyofpimecrolimusinpatientswithfacialseborrheicdermatitisasystematicreviewofrandomizedcontrolledtrials
AT lakhanisom efficacyandsafetyofpimecrolimusinpatientswithfacialseborrheicdermatitisasystematicreviewofrandomizedcontrolledtrials
AT egaimimusab efficacyandsafetyofpimecrolimusinpatientswithfacialseborrheicdermatitisasystematicreviewofrandomizedcontrolledtrials
AT idrisosama efficacyandsafetyofpimecrolimusinpatientswithfacialseborrheicdermatitisasystematicreviewofrandomizedcontrolledtrials
AT elkhalifamohamed efficacyandsafetyofpimecrolimusinpatientswithfacialseborrheicdermatitisasystematicreviewofrandomizedcontrolledtrials